Quick Answer
Crinetics Pharmaceuticals, Inc. reported R&D Expense of $332.06 million for fiscal year 2025.
Crinetics Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $332.06M | +38.3% |
| 2024 | $240.16M | +42.5% |
| 2023 | $168.53M | +29.4% |
| 2022 | $130.22M | +54.6% |
| 2021 | $84.25M | +47.8% |
| 2020 | $57.00M | +37.3% |
| 2019 | $41.51M | +69.6% |
| 2018 | $24.48M | +165.1% |
| 2017 | $9.23M | +81.0% |
| 2016 | $5.10M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $90.46M | +46.1% | +12.7% |
| June 30, 2025 | $80.30M | +37.6% | +5.3% |
| March 31, 2025 | $76.24M | +42.9% | +23.2% |
| September 30, 2024 | $61.91M | +41.2% | +6.1% |
| June 30, 2024 | $58.34M | +43.6% | +9.4% |
| March 31, 2024 | $53.34M | +38.7% | +21.7% |
| September 30, 2023 | $43.84M | +37.1% | +7.9% |
| June 30, 2023 | $40.64M | +23.2% | +5.6% |
- Crinetics Pharmaceuticals, Inc. showed an increase of +38.3% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Crinetics Pharmaceuticals, Inc.’s r&d expense has grown by 6410.9% (from $5.10 million to $332.06 million).
- The most recent figure is from Crinetics Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: